Vitamin E ( DrugBank: Vitamin E )

---

11 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	2
6	Parkinson disease	1
13	Multiple sclerosis/Neuromyelitis optica	0
20	Adrenoleukodystrophy	1
46	Malignant rheumatoid arthritis	1
90	Retinitis pigmentosa	1
96	Crohn disease	1
97	Ulcerative colitis	2
206	Fragile X syndrome	2
299	Cystic fibrosis	1
317	Trifunctional protein deficiency	1

2. Amyotrophic lateral sclerosis

---

Clinical trials : 645 /  Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04140136 (ClinicalTrials.gov)	June 17, 2019	21/10/2019	The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS)	The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS) : A Pilot Exploratory Study	Amyotrophic Lateral Sclerosis	Dietary Supplement: Tocotrienols;Dietary Supplement: Placebo	University of Malaya	NULL	Recruiting	N/A	N/A	All	20	Phase 2	Malaysia
2	NCT00372879 (ClinicalTrials.gov)	December 2006	5/9/2006	Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS	Randomized Crossover Design Trial of Vitamin E vs Placebo for Treatment of Cramps in Amyotrophic Lateral Sclerosis.	Amyotrophic Lateral Sclerosis	Dietary Supplement: Vitamin E	Lawson Health Research Institute	NULL	Completed	18 Years	N/A	Both	32	Phase 3	Canada

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00740714 (ClinicalTrials.gov)	December 2008	22/8/2008	Effects of Coenzyme Q10 (CoQ) in Parkinson Disease	Effects of Coenzyme Q10 in Parkinson Disease - Phase III	Parkinson Disease	Drug: Coenzyme Q10 with vitamin E;Drug: placebo with vitamin E	Weill Medical College of Cornell University	National Institute of Neurological Disorders and Stroke (NINDS);University of Rochester	Terminated	30 Years	N/A	All	600	Phase 3	United States;Canada

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

20. Adrenoleukodystrophy

---

Clinical trials : 61 /  Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01495260 (ClinicalTrials.gov)	September 2011	28/11/2011	A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants	A Clinical Trial for Adrenomyeloneuropathy (AMN): Validation of Biomarkers of Oxidative Stress, and Efficacy, Tolerance and Safety of a Mixture of the Antioxidants N-acetylcysteine, Lipoic Acid and Vitamin E	Adrenomyeloneuropathy	Drug: N-acetylcysteine;Drug: lipoic acid;Drug: vitamin E	Onofre, Aurora Pujol, M.D.	Ministerio de Sanidad, Servicios Sociales e Igualdad;Fundacion Hesperia	Completed	18 Years	64 Years	All	13	Phase 2	Spain

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00399282 (ClinicalTrials.gov)	October 2006	13/11/2006	Omega-3 and Vitamin E Supplementation in Patients With Rheumatoid Arthritis	Comparison of the Effects of Simultaneous Administration of Vitamin E and Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Omega-3 and Vitamin E supplementation	Shahid Beheshti Medical University	NULL	Completed	16 Years	75 Years	Both	75	Phase 1	Iran, Islamic Republic of

90. Retinitis pigmentosa

---

Clinical trials : 147 /  Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00000114 (ClinicalTrials.gov)	May 1984	23/9/1999	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa		Retinitis Pigmentosa	Drug: Vitamin E;Drug: Vitamin A	National Eye Institute (NEI)	NULL	Completed	18 Years	49 Years	Both		Phase 3	NULL

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00152841 (ClinicalTrials.gov)	June 2002	7/9/2005	Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis	Effect of Iron and Antioxidant Vitamins on Disease Activity and Oxidative Stress in Inflammatory Bowel Disease (IBD)	Crohn's Disease;Ulcerative Colitis;Mild or Moderate Anaemia	Drug: Iron supplement 300-600 mg/day;Drug: Vitamin E 800IU	University Health Network, Toronto	Crohn's and Colitis Foundation	Terminated	18 Years	N/A	Both	30	Phase 2	Canada

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03594708 (ClinicalTrials.gov)	April 30, 2018	19/1/2018	Immunonutrition in Ulcerative Colitis	Impact of Immunonutrition Supplementation Combining Fermentable Fiber, Omega-3 Fatty Acids, Vitamin D, Vitamin E, and Zinc on Intestinal Inflammation, Gut Microbial Activity, and Severity of Symptoms in Ulcerative Colitis Patients	Ulcerative Colitis	Dietary Supplement: Nutrition supplement;Dietary Supplement: Placebo supplement	Baptist Memorial Health Care Corporation	NULL	Unknown status	18 Years	N/A	All	30	N/A	United States
2	NCT00152841 (ClinicalTrials.gov)	June 2002	7/9/2005	Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis	Effect of Iron and Antioxidant Vitamins on Disease Activity and Oxidative Stress in Inflammatory Bowel Disease (IBD)	Crohn's Disease;Ulcerative Colitis;Mild or Moderate Anaemia	Drug: Iron supplement 300-600 mg/day;Drug: Vitamin E 800IU	University Health Network, Toronto	Crohn's and Colitis Foundation	Terminated	18 Years	N/A	Both	30	Phase 2	Canada

206. Fragile X syndrome

---

Clinical trials : 108 /  Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-005460-42-ES (EUCTR)	07/07/2016	20/04/2016	Clinical trial to evaluate ascorbic acid (vitamin C) and tocopherol (vitamin E) in combination versus placebo for the treatment of cognitive and behavioral disorders in children with fragile x syndrome	Phase III clinical trial, double-blind, cross-way, to evaluate the safety and efficacy ascorbic acid (vitamin C) and tocopherol (vitamin E) combination versus placebo for the treatment of cognitive and behavioral disorders in children with fragile x syndrome	Fragile x syndrome MedDRA version: 19.0;Level: PT;Classification code 10017324;Term: Fragile X syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: Vitamin C INN or Proposed INN: Vitamin C Other descriptive name: ACIDUM ASCORBICUM D6 Product Name: Vitamin E INN or Proposed INN: Vitamin E Other descriptive name: TOCOPHERYL ACETATE	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	NULL	Not Recruiting			Female: no Male: yes		Phase 3	Spain
2	NCT01329770 (ClinicalTrials.gov)	December 2010	29/3/2011	Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome	Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome	Fragile X Syndrome	Dietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E);Dietary Supplement: Placebo	Yolanda de Diego Otero	NULL	Completed	6 Years	18 Years	Male	30	Phase 2	Spain

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-001007-38-FR (EUCTR)	25/04/2007	26/03/2007	STUDY OF THE LONG TERM BIOLOGICAL EFFICACY AND TOLERABILITY OF VEDROP (VITAMIN E-TPGS FORMULATION) AFTER DAILY ORAL ADMINISTRATION IN 30 PAEDIATRIC PATIENTS WITH CYSTIC FIBROSIS - 1ORP2	STUDY OF THE LONG TERM BIOLOGICAL EFFICACY AND TOLERABILITY OF VEDROP (VITAMIN E-TPGS FORMULATION) AFTER DAILY ORAL ADMINISTRATION IN 30 PAEDIATRIC PATIENTS WITH CYSTIC FIBROSIS - 1ORP2	Paediatric patient who present a cystic fibrosis	Product Name: VEDROP Product Code: VITAMIN E - TGPS INN or Proposed INN: d-a-tocopheryl PEG 1000 succinate	ORPHAN	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France

317. Trifunctional protein deficiency

---

Clinical trials : 4 /  Drugs : 9 - (DrugBank : 4) / Drug target gene : 1 - Drug target pathway : 1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00840112 (ClinicalTrials.gov)	July 2010	9/2/2009	Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy	Vitamin E Treatment for LCHAD Associated Neuropathy	Peripheral Neuropathy;Mitochondrial Trifunctional Protein Deficiency	Dietary Supplement: Vitamin E supplement	Oregon Health and Science University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Oregon State University	Terminated	7 Years	N/A	Both	1	N/A	United States

Back to top